{"analyses":[{"ciLowerLimit":"-9.02","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.55","groupDescription":"Percentage of Participants With RBC-transfusion Independence","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.573","pValueComment":"P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test.","paramType":"Absolute Rate Difference","paramValue":"3.27","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-25.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"18.97","groupDescription":"Percentage of Participants With Platelet-transfusion Independence","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.477","pValueComment":"P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test.","paramType":"Absolute Rate Difference","paramValue":"-3.43","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3"},{"groupId":"OG001","value":"47.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Percentage of Participants With RBCs-transfusion Independence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9"},{"groupId":"OG001","value":"45.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Percentage of Participants With Platelet-transfusion Independence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"129"}],"units":"Participants"}],"description":"A participant was defined as RBC or platelet-transfusion independent if he/she received no RBC or platelet transfusions for a period of at least 8 weeks before the first dose of study drug through 30 days after the last dose of any study drug. Rate of transfusion independence was defined as number of participants who became transfusion independent divided by the number of participants who were transfusion dependent at Baseline.","groups":[{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG001","title":"Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized. Overall number analyzed is the number of participants from a subset of the ITT Population who were transfusion dependent at Baseline. Number analyzed is the number of participants who were transfusion dependent at Baseline for the specified category.","reportingStatus":"POSTED","timeFrame":"Up to approximately 42 months","title":"Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence","type":"SECONDARY","unitOfMeasure":"percentage of participants"}